<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contraception: Counseling for females with obesity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contraception: Counseling for females with obesity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Contraception: Counseling for females with obesity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison Edelman, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bliss Kaneshiro, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Courtney A Schreiber, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Use of safe and effective contraception is essential for preventing unintended pregnancy in women of all body sizes. When counseling women with obesity about contraception, it is important to consider how obesity may affect the safety and efficacy of various contraceptive methods. All contraceptive methods, including the intrauterine devices, <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a>, and combined hormonal contraceptives, are appropriate for use in women with obesity.</p><p>For the purposes of this topic, "woman" refers to any patient who has female reproductive organs and the potential to be pregnant. Clinicians should also consider the contraceptive needs of transgender men and gender nonbinary persons. This topic will address the effects of obesity on contraceptive selection, safety, efficacy, and use. Related topics on fertility and pregnancy in women with obesity are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/411.html" rel="external">"Fertility and pregnancy after bariatric surgery"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H193747533"><span class="h1">FACTORS TO CONSIDER</span></p><p class="headingAnchor" id="H1274362518"><span class="h2">Population need for contraception</span><span class="headingEndMark"> — </span>Although obesity can affect fecundity, the vast majority of women with obesity ovulate regularly and are fertile. There is no evidence that obesity affects contraceptive adherence/compliance [<a href="#rid1">1</a>] or frequency of sexual intercourse [<a href="#rid2">2</a>]. Despite the need for contraception, a national survey in the United States noted that sexually active women of reproductive age with obesity were significantly less likely to use contraception than women of normal weight [<a href="#rid3">3</a>]. It was unclear whether the disparity was due to patient, provider, and/or systems issues. In addition, because contraceptive clinical trials initially excluded overweight or obese women, evidence regarding contraceptive effectiveness and safety for this population is limited [<a href="#rid4">4,5</a>]. However, any risk associated with a contraceptive method needs to be balanced with the risks from unintended pregnancy, particularly for women with obesity. (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management"</a>.)</p><p class="headingAnchor" id="H3784910425"><span class="h2">Pharmacokinetic alterations of obesity</span><span class="headingEndMark"> — </span>Obesity increases metabolic rate, clearance of hepatically metabolized drugs, circulating blood volume, and absorption of contraceptive steroids by adipose tissue. As a result of these changes, women with obesity may take longer to achieve a therapeutic level of contraceptive hormones when starting oral hormonal contraceptives, or after the hormone-free interval, compared with normal-weight women [<a href="#rid6">6,7</a>]. As a result of these findings, concerns have been raised that changes in serum drug levels in women with obesity may increase the risk for contraceptive failure, but data are limited and inconsistent [<a href="#rid4">4,6-13</a>]. (See <a class="local">'Efficacy'</a> below and <a class="local">'Contraceptive patch'</a> below.)</p><p class="headingAnchor" id="H2227716674"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>Our approach to contraceptive counseling does not vary based on weight/body mass index (BMI, kg/m<sup>2</sup>) unless the patient has additional comorbidities. In our practice, we review all contraceptive methods with all patients no matter their weight/BMI  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). We do inform the patient that obesity does increase the baseline risk for deep venous thrombosis and, depending on age and other comorbidities, that methods that contain estrogen may not be the safest choice. Factors that are considered in contraceptive selection include patient preferences, efficacy, side effects, duration of action, and noncontraceptive benefits, among others. Details on how to approach contraceptive counseling and method selection are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a>.)</p><p>While the woman ultimately determines her contraceptive choice, we take the following approach to counseling women with obesity: </p><p class="bulletIndent1"><span class="glyph">●</span>For women who desire permanent sterilization, we review the options of both female and male sterilization procedures. We discuss that male vasectomy is associated with fewer risks and complications as it is an outpatient procedure performed on external anatomy under local anesthesia. By contrast, female fallopian tube ligation or excision requires intra-abdominal surgery, typically with laparoscopy, under general anesthesia. Women of higher weight/BMI can have an increased risk of adverse events with surgery, including postoperative infection. Long-acting reversible methods, like intrauterine devices (IUDs) and implants, should also always be discussed with a woman considering a permanent method, as these methods provide the same level of protection. (See <a class="local">'Surgical sterilization'</a> below and <a class="local">'Most effective reversible methods'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For a woman who desires reversible contraception, we ask if she has identified a method that she is interested in and what she wants out of a method (efficacy, safety, noncontraceptive benefits, concerns about side effects). We review the advantages and disadvantages of the method she has identified but then also inform her of other methods that might meet her needs. We also take some time to review the most effective reversible methods like IUDs and the <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a>  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). As these methods are not estrogen-containing and do not rely on compliance, they are extremely safe and effective for women with obesity or other comorbidities. Progestin-containing methods like the <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) IUD or the etonogestrel implant can be protective of the endometrium and thus reduce the risk of endometrial hyperplasia, a concern in women of higher weight. However, IUD insertion can be challenging, particularly for women with class III obesity (≥40 kg/m<sup>2</sup>) or higher. (See <a class="local">'Intrauterine contraception'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women who decline the IUDs and implant, we next review the various hormonal contraceptive methods, which include depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA), estrogen-progestin combined hormonal contraceptives (oral pill, transdermal patch, and vaginal ring), and progestin-only pills. These methods are considered as having moderate efficacy  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). The most important factor in maintaining the effectiveness of these methods is consistent use; body weight may play a small role in failure if adherence is poor [<a href="#rid5">5,14</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For women who desire a longer-acting reversible hormonal contraceptive, <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is injected every 12 weeks. DMPA use can be associated with weight gain in adolescent women. (See <a class="local">'Depot medroxyprogesterone acetate'</a> below.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For women who desire combined estrogen-containing contraceptives and have no contraindications to estrogen use, the decision to use the pill, transdermal patch, or vaginal ring should be based on the mode of hormonal delivery that the patient feels fits with her lifestyle. (See <a class="local">'Combined estrogen-progestin contraceptives'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For women who prefer to avoid the above hormonal methods or who have contraindications to estrogen exposure but do not wish to use <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a>, progestin-only pills (POPs) are the next option. Although the available evidence is limited, POPs do not appear to be less effective or associated with weight gain in women with obesity [<a href="#rid15">15</a>]. However, these products require consistent use to maintain efficacy. (See <a class="local">'Progestin-only pills'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericoital contraceptives are available for women who desire contraception only at the time of vaginal intercourse. These methods include the single-size diaphragm, cervical cap, spermicidal sponge, and spermicide. While these methods are unlikely to be impacted by body weight, supporting data are sparse. They are also less effective forms of contraception and require both user skill and motivation  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). (See <a class="local">'Pericoital contraceptive methods'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Barrier contraceptives include male and female condoms. These can be used by any patient, but the efficacy is lower compared with the above methods  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). However, these methods can be combined with any of the above methods as a secondary (ie, backup) contraceptive to increase contraceptive efficacy or to provide protection from sexually transmitted infections. (See <a class="local">'Barrier methods'</a> below.)</p><p></p><p>The evidence for our approach is reviewed below.</p><p class="headingAnchor" id="H1931459035"><span class="h1">COUNSELING POINTS</span></p><p class="headingAnchor" id="H2269706994"><span class="h2">Safety</span></p><p class="headingAnchor" id="H2347971704"><span class="h3">Coexistent medical issues</span><span class="headingEndMark"> — </span>As women with obesity, especially those with comorbidities, are at higher risk of pregnancy-related complications, avoidance of unintended pregnancy is particularly important. In general, healthy women with obesity can safely use any contraceptive method following appropriate method-specific counseling regarding potential risks and benefits. Country-specific and world health guidelines exist to guide contraceptive selection for women who also have specific medical conditions or states (ie, lactation). These guidelines are generally similar; clinicians should use the one from their country or the one that best matches their patient population. When choosing contraception, the specific risks of the method relative to any underlying medical disorders must also be balanced against the risks of unintended pregnancy.</p><p>World Health Organization (WHO) – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=5470" target="_blank">Medical Eligibility Criteria (MEC) for contraceptive use</a></p><p class="bulletIndent1"><span class="glyph">●</span>US Centers for Disease Control and Prevention (CDC) – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYMabpkGTohBYdmv9Chf4nyxhXv3BXhtKgT5nV2ZyDrkT1PiNmt3KeIy5H8eCIWwT5krtNV37tK%2Fa8yNDFz12Fa0%3D&amp;TOPIC_ID=5470" target="_blank">CDC MEC</a> and <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fpdf%2Fsummary-chart-us-medical-eligibility-criteria_508tagged.pdf&amp;token=jEVGVo6WqsDq698K1C6vDPPjIqTfzg54vW4qWS3doblDMO%2BX3NN%2Fro6R0xwK%2FI6IOwBh6DyNhV%2Fq6vrv3T8nCaRCrZsEC%2BWz9FPYFmXFzWEhd9uzeVTKQGeWKf6mT23Z1X5qsRVoFq27I5l%2B8ZoObQ%3D%3D&amp;TOPIC_ID=5470" target="_blank">summary table</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Faculty of Sexual &amp; Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists – <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fsrh.org%2Fstandards-and-guidance%2Fdocuments%2Fukmec-2016%2F&amp;token=%2BMu8C06jYeg0jUEwqKBGFW7cSS1%2Fi9M4Bp%2F8kwj4VpwPtdxCQQlEb%2BmTvUQgVKDGPGvtrMFGAZ5NVt%2BcFuSeWcwBIDK1G%2F%2BpOKD%2B5iNrFUU%3D&amp;TOPIC_ID=5470" target="_blank">United Kingdom MEC</a> </p><p></p><p class="headingAnchor" id="H1019509741"><span class="h3">Risk of thromboembolism</span><span class="headingEndMark"> — </span>Obesity increases the risks of cardiovascular disease, stroke, and thromboembolism (see  <a class="medical medical_review" href="/d/html/5370.html" rel="external">"Overweight and obesity in adults: Health consequences", section on 'Cardiovascular'</a>). The risk of these problems is further elevated by independent characteristics such as increasing age and smoking. Thus, contraceptive selection for women with obesity must account for the biologic impact of obesity on thromboembolic risk, medical comorbidities, and other risk factors, especially when considering estrogen-containing contraceptives that also increase the risk of thromboembolism. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>No increased risk</strong> – For women with obesity who wish to avoid any increased risk of thromboembolism, reversible contraceptive options include the <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper intrauterine device</a> (IUD), pericoital contraceptives, and barrier contraceptives. Surgical sterilization does not increase the risk of thrombosis in any patient population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small absolute increased risk</strong> – All progestin-only contraceptives are available for unrestricted use in otherwise healthy women with obesity [<a href="#rid15">15-18</a>]. Although there are somewhat conflicting data regarding the risk of thromboembolism with the <a class="drug drug_general" data-topicid="8870" href="/d/drug information/8870.html" rel="external">etonogestrel implant</a> and depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA), any increased risk attributable to the hormone itself appears to be small. Similar findings have been reported for progestin-only oral pills [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant", section on 'Risk of thromboembolic event'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Cardiovascular and thromboembolic risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Confirmed increased risk</strong> – For combined estrogen-progestin hormonal contraceptives (CHC; ie, oral pill, transdermal patch, and vaginal ring), both hormonal components can impact the thrombosis risk, but the greater risk comes from the estrogen component. While the relative risk of thromboembolism is increased with CHC use [<a href="#rid20">20</a>], the absolute risk is still considered acceptable for otherwise healthy women with obesity (ie, "the advantages of using the method generally outweigh the theoretical or proven risks") [<a href="#rid16">16,18</a>]. The risk of venous thromboembolism (VTE) in obese women who use CHCs is less than the VTE risk associated with obesity and pregnancy or the postpartum period [<a href="#rid21">21,22</a>]. Although there are conflicting data on the risk of acute myocardial infarction and stroke in women with obesity who use CHCs, the absolute risk appears to be low [<a href="#rid23">23,24</a>]. </p><p></p><p class="bulletIndent1">While the WHO and the CDC do not provide age limits for CHC use in healthy women with obesity, the United Kingdom MEC advise against CHC use in women with a body mass index (BMI) ≥35 kg/m<sup>2</sup> [<a href="#rid15">15-18</a>]. In our practice, we offer estrogen-progestin contraceptives to women with obesity, including those older than 35 years of age, as long as they do not have other medical contraindications to use of these drugs and are nonsmokers (for women age &gt;35 years). (See  <a class="medical medical_review" href="/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns", section on 'Cardiovascular effects'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Although studies are limited, there is no evidence that any method of contraception is significantly less effective in women with obesity [<a href="#rid5">5,14,15,25</a>]. Thus, women with obesity can be offered all contraceptive methods that are compatible with their other medical conditions; specific discussions by contraceptive method are presented below. Previously, concerns have been raised that the efficacy of oral contraceptives is suboptimal in this population. However, it is important to remember that the overall rate of contraceptive failure is related to several factors, including the inherent effectiveness of the method, adherence and compliance with the method, fecundity of the population, and sexual behavior (eg, rare versus frequent sexual intercourse). Concerns have also been raised that serum drug levels in women with obesity may be insufficient to maintain contraceptive effects, but data are limited and inconsistent [<a href="#rid4">4,6-13</a>]. If contraceptive efficacy is reduced, the magnitude of effect is likely to be small as pharmacokinetic studies have estimated that body weight accounts for only 10 to 20 percent of the variability in hormone levels, which is consistent with normal variability in steroid levels among individuals.</p><p class="headingAnchor" id="H322011697"><span class="h2">Weight gain</span><span class="headingEndMark"> — </span>Weight gain is a concern for many women, particularly women who are already overweight or obese. Fear of weight gain is often cited as a reason women do not initiate or continue hormonal contraception [<a href="#rid26">26</a>]. There is good evidence that use of CHCs, progestin-only pills, intrauterine contraception, and contraceptive implants is not associated with substantial weight gain or discontinuation of a contraceptive due to weight gain [<a href="#rid27">27-31</a>]. Although randomized trials have not reported significant weight gain in <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> users [<a href="#rid32">32,33</a>], observational studies have reported that overweight and obese adolescents gain more weight when using this method than when using oral contraceptives or no contraception [<a href="#rid34">34-37</a>]. A study in adult women found that normal and overweight women gained weight with DMPA use, whereas women with obesity did not [<a href="#rid38">38</a>]. Based on these data, several guidelines label the use of DMPA in adolescent women (&lt;18 years) as category 2, or as "advantages generally outweigh theoretical or proven risks") [<a href="#rid16">16-18</a>]. (See  <a class="medical medical_review" href="/d/html/118540.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits", section on 'Weight changes'</a>.)</p><p class="headingAnchor" id="H1179230284"><span class="h2">Noncontraceptive benefits</span><span class="headingEndMark"> — </span>Obesity is a risk factor for endometrial hyperplasia and endometrial cancer. Both types of IUD and hormonal contraceptives provide endometrial protection and have been associated with a decrease in this risk [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Use of hormonal contraception'</a>.)</p><p class="headingAnchor" id="H1195584760"><span class="h1">CONTRACEPTIVE OPTIONS</span><span class="headingEndMark"> — </span>Women who are obese and desire contraception should be offered the full range of contraceptive options that are compatible with any other medical comorbidities [<a href="#rid5">5,14</a>]. </p><p class="headingAnchor" id="H3923572557"><span class="h2">Surgical sterilization</span><span class="headingEndMark"> — </span>Fallopian tube ligation or excision provide effective contraception, but both processes are associated with longer operating times and more anesthetic and surgical complications in women with obesity compared with women who are not obese [<a href="#rid40">40-43</a>]. If acceptable, male sterilization (ie, vasectomy) avoids the risks of intra-abdominal surgery and general anesthesia.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/101560.html" rel="external">"Overview of female permanent contraception"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8094.html" rel="external">"Vasectomy"</a>.)</p><p></p><p class="headingAnchor" id="H2269710137"><span class="h2">Most effective reversible methods</span><span class="headingEndMark"> — </span>Intrauterine devices (IUDs) and progestin-only implants are the most effective reversible contraceptive methods  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). </p><p class="headingAnchor" id="H2269710205"><span class="h3">Intrauterine contraception</span><span class="headingEndMark"> — </span>IUDs are a preferred contraceptive option for women with obesity who have no contraindications to use of this method and are accepting of it. Both the copper and <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG)-releasing IUDs are highly effective regardless of weight [<a href="#rid14">14-16,18</a>]. The LNG-releasing IUDs have the added benefit of treating abnormal uterine bleeding and endometrial hyperplasia, if present [<a href="#rid14">14,44</a>]. (See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p>A prospective cohort study reported no statistically significant difference in the contraceptive failure rate during the first two to three years of use among IUD users (copper-releasing or LNG-releasing [LNG 52, 20 mcg/day release, total LNG content 52 mg]) who were of normal body mass index (BMI; n = 1584), overweight BMI (n = 1149), or obese BMI (n = 1467): the overall failure rate of less than 1 pregnancy per 100 woman-years did not vary by BMI [<a href="#rid45">45</a>]. The initial efficacy trial of a subsequent lower-dose LNG-releasing IUD (LNG 14; 14 mcg/day release, total LNG content 13.5 mg) included women 38 to 155 kg (mean 68.7 kg) and BMI 16 to 55 kg/m<sup>2</sup> (mean 25.3 kg/m<sup>2</sup>) and did not report lower efficacy for obese study participants.</p><p>Visualizing the cervix and determining the size and direction of the uterus can be challenging in severely obese women during insertion of the device. Optimizing equipment by selecting a large speculum or removing the tip of a condom and placing it over the blades of the speculum can help with exposure [<a href="#rid4">4</a>]. Ultrasound may be helpful to guide insertion. (See  <a class="medical medical_review" href="/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal"</a>.)</p><p class="headingAnchor" id="H2269710211"><span class="h3">Contraceptive implant</span><span class="headingEndMark"> — </span>The LNG and etonogestrel (ENG) contraceptive implants appear to be highly effective in overweight and obese women, although possibly less effective compared with women who weigh less [<a href="#rid5">5</a>]. In a three-year trial of nearly 1000 women randomly assigned to receive the LNG implant, three pregnancies occurred, all in women weighing ≥70 kg at conception, for a cumulative pregnancy rate of 0.4 per 100 woman-years for all LNG users [<a href="#rid46">46</a>]. For nearly 1000 women randomly assigned to the ENG implant, there were no pregnancies in women ≥70 kg compared with three pregnancies in women &lt;70 kg at conception. Because of the small total number of pregnancies in the study and the relatively small number of women ≥70 kg (fewer than 20 percent of subjects), it is unclear whether weight ≥70 kg affects contraceptive implant efficacy and whether there is a true difference in efficacy between LNG and ENG implants at weights ≥70 kg. The trial data are consistent with pharmacologic studies that report plasma hormone concentrations for both ENG and LNG remain above the contraceptive threshold for the approved duration of the device in women with obesity, although these levels may be lower compared with nonobese women [<a href="#rid47">47-49</a>]. It is likely that there is no large difference in contraceptive implant efficacy between women ≥70 kg and those &lt;70 kg. Extending the use of the implant from three to five years has not been sufficiently studied in a population of women weighing over 70 kg; thus, we would not advise extended use of the implant in this population [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p class="headingAnchor" id="H2269710340"><span class="h2">Moderately effective reversible methods</span><span class="headingEndMark"> — </span>Moderately effective reversible contraceptive methods include the combined estrogen-progestin and progestin-only options  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). These methods are generally considered to be as effective in women with obesity compared with normal-weight women, although conflicting data exist [<a href="#rid5">5</a>]. However, use of contraception, even if somewhat less effective, will prevent more pregnancies than no contraception and is always less risky to women with obesity compared with pregnancy [<a href="#rid5">5,51</a>].</p><p class="headingAnchor" id="H625511317"><span class="h3">Depot medroxyprogesterone acetate</span><span class="headingEndMark"> — </span>Depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DMPA) is available as a 150 mg intramuscular injection ("DMPA") and as a 104 mg subcuticular injection ("DMPA-SC"). Both provide effective contraception for obese women [<a href="#rid14">14</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> – A multinational study including 846 women receiving DMPA for one year reported a 12-month pregnancy rate of 0.7±0.4 percent with no impact of body weight [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DMPA-SC</strong> – A study of the contraceptive efficacy of DMPA-SC that included substantial numbers of overweight women and women with obesity reported no pregnancies in 16,023 woman-cycles of use [<a href="#rid53">53</a>]. In addition, a study of the pharmacokinetics of DMPA-SC in class I, II, and III women with obesity versus women with normal BMI reported that median medroxyprogesterone levels remained above the level needed to prevent ovulation, although estradiol levels fluctuated more in women with obesity than normal controls [<a href="#rid54">54</a>]. </p><p></p><p>Women who are acceptable candidates for progestin-only contraception can use either formulation. Neither product is associated with additional weight gain in adult women with obesity, although there are conflicting data for younger women with obesity (less than age 18 years) [<a href="#rid5">5,34,37,55,56</a>]. For all women younger than age 18, <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> use is labeled as category 2 (ie, the advantages of using the method generally outweigh the theoretical or proven risks) because of potential concern for long-term reductions in bone mineral density, although supporting data are limited [<a href="#rid16">16-18</a>]. Of note, the persistence of ovulation suppression following discontinuation of DMPA is related to weight: women with lower body weights conceive sooner than women with higher body weights after stopping the drug. (See  <a class="medical medical_review" href="/d/html/5468.html" rel="external">"Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration", section on 'Return to fertility after discontinuation'</a>.)</p><p><a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">DMPA</a> is designed to be an intramuscular injection. In some women, a longer needle or deltoid injection may be necessary to reach the muscle layer [<a href="#rid15">15</a>]. DMPA-SC does not require any changes in administration for women with obesity.</p><p class="headingAnchor" id="H971328776"><span class="h3">Combined estrogen-progestin contraceptives</span><span class="headingEndMark"> — </span>Women with obesity who have no additional contraindications to estrogen exposure can safely use combined estrogen-progestin contraceptives. The choice of which combined method is related to patient preferences, such as need for daily pill consumption and route of application. Specific information on each of these methods is reviewed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7398.html" rel="external">"Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16682.html" rel="external">"Contraception: Hormonal contraceptive vaginal rings"</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h4">Oral contraceptives</span><span class="headingEndMark"> — </span>The available literature suggests that oral contraceptives are generally effective at pregnancy prevention in women with obesity but may be less forgiving of imperfect use because of altered steroid hormone pharmacokinetics in this group compared with normal-weight users [<a href="#rid5">5-8,57-61</a>]. (See <a class="local">'Pharmacokinetic alterations of obesity'</a> above.)</p><p>We start all women who desire oral contraceptive pills on products containing 20 to 30 mcg of ethinyl estradiol, regardless of the woman's body weight or BMI. Although insufficient evidence exists to recommend a specific estrogen dose or use of a higher-dose rather than a lower-dose oral contraceptive pill, most pharmacokinetic studies in women with obesity used a pill containing 20 mcg ethinyl estradiol and demonstrated ovulation suppression [<a href="#rid7">7,8,13</a>]. We do not start any women on a pill with more than 35 mcg of ethinyl estradiol because of the increased risk of thromboembolism. As women with obesity require more time to achieve steady state levels, these women may benefit from extended-cycle or 24/4 regimens compared with traditional 21/7 regimens [<a href="#rid5">5-8,57-59</a>]. Because 24/4 regimens overall provide higher contraceptive efficacy than 21/7 regimens, we advise 24/4 dosing in all women who desire oral contraceptive pills, regardless of body weight.</p><p>While the data on the impact of obesity on combined oral contraceptive efficacy are mixed, the absolute increased risk of pregnancy appears to be small [<a href="#rid60">60</a>]. In a study including a cohort of more than 55,000 United States women, oral contraceptive pill failure was slightly higher for women with BMI ≥35 kg/m<sup>2</sup> compared with women with BMI &lt;35 (adjusted hazard ratio 1.5, 95% CI 1.3-1.8) [<a href="#rid62">62</a>]. Other epidemiologic studies have reported inconsistent results, with several studies demonstrating a higher risk of pregnancy in obese oral contraceptive pill users [<a href="#rid63">63-65</a>] and others finding no significant association for either combined oral contraceptives or progestin-only pills [<a href="#rid66">66-70</a>].</p><p>The use of oral contraceptives in women with obesity with polycystic ovary syndrome is reviewed separately. (See  <a class="medical medical_review" href="/d/html/7421.html" rel="external">"Treatment of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H28036443"><span class="h4">Contraceptive ring</span><span class="headingEndMark"> — </span>In the absence of data to suggest otherwise, we counsel both obese and normal-weight women similarly regarding contraceptive ring efficacy. The use of contraception prevents more pregnancies than no use of contraception, and adherence/compliance is the biggest issue with effectiveness even if a difference exists regarding BMI.</p><p>All large trials assessing the effectiveness of the estrogen-progestin vaginal rings (sample names NuvaRing, Annovera) have been conducted in nonobese women [<a href="#rid71">71,72</a>]. While a systematic review reported similar efficacy for obese and normal-weight women using any combined hormonal contraception, the study was unable to separate the data for pill, ring, and patch users [<a href="#rid5">5</a>]. A study of 128 pregnancies that resulted from a combined group of pill, patch, or ring users concluded three-year failure rates among women using these methods were not different across BMI categories [<a href="#rid69">69</a>]. However, the methodology used and the possible effect of noncompliance may have masked the actual effect of BMI on contraceptive failure [<a href="#rid73">73</a>].</p><p>A small pharmacokinetic study in etonogestrel/ethinyl estradiol ring users reported that follicular development was minimal in both obese and normal BMI women [<a href="#rid74">74</a>]. Another small study noted hormone levels remained in the therapeutic range up to 35 days after ring insertion in both obese and normal BMI ring users [<a href="#rid75">75</a>]. Although reassuring, these studies were conducted over only one cycle in small groups of women and immediately following a cycle of oral contraceptive pill use; thus, efficacy could not be determined. The initial approval studies for the segesterone/ethinyl estradiol ring did not include women with BMIs above 29 kg/m<sup>2 </sup>[<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H780929068"><span class="h4">Contraceptive patch</span><span class="headingEndMark"> — </span>The use of transdermal contraception by patients with obesity varies by the patch type. Detailed discussions of contraceptive patch types and efficacy are presented in detail separately. (See  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Patch types'</a> and  <a class="medical medical_review" href="/d/html/5425.html" rel="external">"Contraception: Transdermal contraceptive patches", section on 'Efficacy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethinyl estradiol and norelgestromin-containing patch</strong> – The ethinyl estradiol and norelgestromin (EE/N, sample name Xulane) patch is labeled as contraindicated for individuals with a BMI ≥30 kg/m<sup>2</sup> [<a href="#rid76">76</a>]. A pooled analysis of three large studies examining the efficacy of the EE/N contraceptive patch reported contraceptive failure was low and uniformly distributed across the range of body weights &lt;90 kg (198 pounds) but suggested the EE/N patch may be less effective in the subgroup of women ≥90 kg (198 lbs) [<a href="#rid77">77</a>]. In this analysis, 5 of the 15 pregnancies in EE/N patch users occurred in the 83 women (3 percent of study subjects) who weighed ≥90 kg. The small number of pregnancies in this pooled analysis made it impossible to provide a good estimate of the excess risk of contraceptive failure in individuals weighing ≥90 kg. In addition, studies of the EE/N contraceptive patch have included individuals who are as much as 35 percent above their ideal body weight, which contrasts from most oral contraceptive pill studies that excluded individuals who were more than 20 percent above ideal body weight and further complicates the understanding of patch efficacy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethinyl estradiol and levonorgestrel-containing patch</strong> – The US Food and Drug Administration-approved package label states that the ethinyl estradiol and <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (EE/LNG, sample name Twirla) patch is contraindicated in people with a BMI &gt;30 kg/m<sup>2</sup> because of concerns for diminished efficacy and elevated venous thromboembolism (VTE) risk [<a href="#rid78">78</a>]. Though there is a concern for diminished efficacy, available data suggest the risk of VTE with the EE/LNG patch is similar to that of other oral combined estrogen-progestin contraceptive pills [<a href="#rid79">79</a>].</p><p></p><p class="headingAnchor" id="H3239887740"><span class="h3">Progestin-only pills</span><span class="headingEndMark"> — </span>There are no studies examining the contraceptive efficacy of progestin-only pills in obese women. All women, regardless of body weight, should be informed that typical-use failure rates of oral contraceptives, including progestin-only pills, are 9 percent [<a href="#rid80">80</a>]. Therefore, women who desire more effective contraceptives should consider a different method.</p><p class="headingAnchor" id="H4212665181"><span class="h2">Less effective reversible methods</span><span class="headingEndMark"> — </span>These methods are event-based forms of contraception, which makes them more prone to user-related contraceptive failure  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). There are no data that obesity specifically lowers the contraceptive efficacy of these methods.</p><p class="headingAnchor" id="H14"><span class="h3">Pericoital contraceptive methods</span><span class="headingEndMark"> — </span>No studies have evaluated the efficacy of pericoital contraceptives (ie, single-size diaphragm, cervical cap, spermicidal sponge) in obese users. Theoretically, obesity should not affect the safety or efficacy of these contraceptives, but fitted diaphragms should be resized if the patient has a large change in weight. (See  <a class="medical medical_review" href="/d/html/3265.html" rel="external">"Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"</a>.)</p><p class="headingAnchor" id="H2162651802"><span class="h3">Barrier methods</span><span class="headingEndMark"> — </span>Condoms (male and female) are barrier contraceptives. If a barrier method is used simultaneously with a pericoital method (eg, male condom and diaphragm, cervical cap, or vaginal spermicide), efficacy increases substantially. While less effective as contraception  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>), barrier methods do provide protection from sexually transmitted infections. (See  <a class="medical medical_review" href="/d/html/5471.html" rel="external">"Internal (formerly female) condoms"</a> and  <a class="medical medical_review" href="/d/html/5463.html" rel="external">"External (formerly male) condoms"</a>.)</p><p class="headingAnchor" id="H155018281"><span class="h1">EMERGENCY CONTRACEPTION</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper intrauterine device</a> is the most reliable emergency contraceptive (EC) regardless of body mass index (BMI) and is not impacted by increasing BMI. However, oral drugs for EC may be less effective in overweight women and women with obesity compared with normal-weight women, particularly <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a>. Data on EC use in those with obesity are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/5475.html" rel="external">"Emergency contraception", section on 'Impact of body weight'</a>.)</p><p class="headingAnchor" id="H3947330252"><span class="h1">CONTRACEPTION PRE- AND POST-BARIATRIC SURGERY</span><span class="headingEndMark"> — </span>Women who are planning bariatric surgery and using any estrogen-containing contraceptive are advised to discontinue the contraceptive at least one month before surgery to reduce the risk of postoperative thromboembolism. An alternate method should be employed. Women using intrauterine devices (IUDs), etonogestrel implants, or progestin-only methods do not need to stop or alter their contraceptives. (See  <a class="medical medical_review" href="/d/html/4814.html" rel="external">"Perioperative medication management", section on 'Oral contraceptives'</a>.)</p><p>Postoperatively, the weight loss that accompanies bariatric surgery can enhance fecundity in women who were subfertile because of oligo-ovulation or anovulation [<a href="#rid81">81-83</a>]. Thus, these women ideally have a contraceptive plan in place prior to their surgery. (See  <a class="medical medical_review" href="/d/html/411.html" rel="external">"Fertility and pregnancy after bariatric surgery"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Women who undergo restrictive bariatric procedures, including vertical banded gastroplasty, laparoscopic adjustable gastric band, or laparoscopic sleeve gastrectomy, can safely and effectively begin or restart oral contraceptives once they are mobile [<a href="#rid18">18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women who undergo malabsorptive procedures, such as biliopancreatic diversion, jejunoileal bypass, or Roux-en-Y bypass, may have reduced absorption of oral contraceptives, although there does not appear to be a substantial decrease in efficacy for these women [<a href="#rid84">84-86</a>]. The paucity of data makes patient counseling difficult. A 2010 systematic review of five studies reported an increased pregnancy rate in women with biliopancreatic diversion, but the total number of both patients and pregnancies was small (two pregnancies among nine oral contraceptive users) and based on one study [<a href="#rid86">86</a>]. In the same review, two pharmacokinetic studies evaluated women with jejunoileal bypass. One study reported lower plasma levels of norethisterone and <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> while the other study reported identical to elevated plasma levels of D-norgestrel; the variation in the second study correlated with the remaining ratio of jejunum and ileum left in continuity. Women with a 1:3 ratio had significantly higher plasma levels. Another study of oral desogestrel found no clinically significant changes in etonogestrel pharmacokinetics before and after Roux-en-Y gastric bypass surgery.</p><p></p><p class="bulletIndent1">Based on the limited available data above, we take a conservative approach and advise avoiding oral contraceptive pills in women who have undergone malabsorptive procedures and suggest use of any nonoral method (ie, the vaginal ring, transdermal patch, IUDs, or progestin-only implant or injection), which is consistent with the approaches taken by the American College of Obstetricians and Gynecologists and the US Centers for Disease Control and Prevention, [<a href="#rid14">14,16,87,88</a>]. The United Kingdom Medical Eligibility Criteria do not place a restriction based on surgery type but instead advise avoiding all combined hormonal contraceptives in women who have had bariatric surgery but still have a body mass index of 35 or greater [<a href="#rid17">17</a>]. The World Health Organization does not list bariatric surgery as a medical factor but advises that combined hormonal contraceptives not be used in women undergoing major surgery with prolonged immobilization [<a href="#rid18">18</a>]. </p><p></p><p class="headingAnchor" id="H1911344144"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112268.html" rel="external">"Society guideline links: Contraception"</a> and  <a class="medical medical_society_guidelines" href="/d/html/111344.html" rel="external">"Society guideline links: Obesity in adults"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility</strong> – Although obesity can affect fecundity, the vast majority of women with obesity ovulate regularly and are fertile. There is no evidence that obesity affects contraceptive adherence/compliance or frequency of sexual intercourse. (See <a class="local">'Population need for contraception'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic impact on hormonal contraceptives</strong> – Obesity increases metabolic rate, clearance of hepatically metabolized drugs, circulating blood volume, and absorption of contraceptive steroids by adipose tissue. As a result of these changes, women with obesity take twice as long to achieve therapeutic steady-state levels of contraceptive hormones. (See <a class="local">'Pharmacokinetic alterations of obesity'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraceptive counseling</strong> – In our practice, we review all contraceptive methods with all patients. Factors that are considered in contraceptive selection include patient preferences, side effects, duration of action, noncontraceptive benefits, and efficacy  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>), among others. Details on how to approach contraceptive counseling and method selection are presented elsewhere. (See <a class="local">'Our approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraceptive selection</strong> – In general, healthy individuals with obesity can safely use any contraceptive method following appropriate method-specific counseling regarding potential risks and benefits. Individual countries and the World Health Organization have published <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=5470" target="_blank">Medical Eligibility Criteria</a> to guide contraceptive selection in women with medical issues. When choosing contraception, the specific risks of the method relative to any underlying medical disorders must also be balanced against the risks of unintended pregnancy in this group. (See <a class="local">'Coexistent medical issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Long-acting reversible contraceptives</strong> – Regardless of body weight, intrauterine devices (IUDs, either copper or levonorgestrel-releasing) and implants (etonogestrel) are the most effective contraceptive methods  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). These methods are not associated with weight gain (compared with depot <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> [DMPA]) and do not expose the woman to potential risks associated with estrogen-containing contraceptives. (See <a class="local">'Efficacy'</a> above and <a class="local">'Weight gain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormonal contraceptive methods</strong> – Moderately effective reversible contraceptive methods include the combined estrogen-progestin and progestin-only options  (<a class="graphic graphic_figure graphicRef119765" href="/d/graphic/119765.html" rel="external">figure 1</a>). These methods are generally considered to be as effective in women with obesity compared with normal-weight women, although conflicting data exist. However, use of hormonal contraception, even if somewhat less effective, will prevent more pregnancies than no contraception and is always less risky to women with obesity compared with pregnancy. The decision to use the pill, patch, or ring should be based on the mode of hormonal delivery that the patient feels fits with her lifestyle. For all women who choose oral contraception, we start with a pill containing 20 to 30 mcg of ethinyl estradiol. (See <a class="local">'Moderately effective reversible methods'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emergency contraception</strong> – The <a class="drug drug_general" data-topicid="93719" href="/d/drug information/93719.html" rel="external">copper IUD</a> is the most reliable emergency contraceptive (EC) regardless of body mass index (BMI) and is not impacted by increasing BMI. However, oral drugs for EC may be less effective in overweight women and women with obesity compared with normal-weight women, particularly <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a>. (See <a class="local">'Emergency contraception'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of bariatric surgery</strong> – Bariatric surgery procedures causing malabsorption, such as biliopancreatic diversion or jejunoileal bypass, may interfere with the absorption of oral contraceptives, thus reducing their effectiveness. If hormonal contraception is used, we advise nonoral hormonal contraceptives over oral hormonal contraceptives. (See <a class="local">'Contraception pre- and post-bariatric surgery'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Society of Family Planning, Higginbotham S. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception 2009; 80:583.</a></li><li><a class="nounderline abstract_t">Kaneshiro B, Jensen JT, Carlson NE, et al. Body mass index and sexual behavior. Obstet Gynecol 2008; 112:586.</a></li><li><a class="nounderline abstract_t">Chuang CH, Chase GA, Bensyl DM, Weisman CS. Contraceptive use by diabetic and obese women. Womens Health Issues 2005; 15:167.</a></li><li><a class="nounderline abstract_t">Grimes DA, Shields WC. Family planning for obese women: challenges and opportunities. Contraception 2005; 72:1.</a></li><li><a class="nounderline abstract_t">Lopez LM, Bernholc A, Chen M, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev 2016; :CD008452.</a></li><li><a class="nounderline abstract_t">Edelman AB, Carlson NE, Cherala G, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009; 80:119.</a></li><li><a class="nounderline abstract_t">Edelman AB, Cherala G, Munar MY, et al. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception 2013; 87:220.</a></li><li><a class="nounderline abstract_t">Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010; 81:474.</a></li><li><a class="nounderline abstract_t">Speerhas R. Drug metabolism in malnutrition and obesity: clinical concerns. Cleve Clin J Med 1995; 62:73.</a></li><li><a class="nounderline abstract_t">Ravussin E, Burnand B, Schutz Y, Jéquier E. Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects. Am J Clin Nutr 1982; 35:566.</a></li><li><a class="nounderline abstract_t">Stadel BV, Sternthal PM, Schlesselman JJ, et al. Variation of ethinylestradiol blood levels among healthy women using oral contraceptives. Fertil Steril 1980; 33:257.</a></li><li><a class="nounderline abstract_t">Fishman J, Boyar RM, Hellman L. Influence of body weight on estradiol metabolism in young women. J Clin Endocrinol Metab 1975; 41:989.</a></li><li><a class="nounderline abstract_t">Westhoff CL, Torgal AH, Mayeda ER, et al. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol 2010; 116:275.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions. Obstet Gynecol 2019; 133:e128. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">FSRH Guideline (April 2019) Overweight, Obesity and Contraception. BMJ Sex Reprod Health 2019; 45:1.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Medical Eligibility Criteria for Contraceptive Use (UK MEC 2005/2006), Faculty of Family Planning and Reproductive Health Care, London (2006).</li><li class="breakAll">Medical Eligibility Criteria for Contraceptive Use, World Health Organization, Geneva 2015.</li><li><a class="nounderline abstract_t">Cockrum RH, Soo J, Ham SA, et al. Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age. Obstet Gynecol 2022; 140:477.</a></li><li><a class="nounderline abstract_t">Rosano GMC, Rodriguez-Martinez MA, Spoletini I, Regidor PA. Obesity and contraceptive use: impact on cardiovascular risk. ESC Heart Fail 2022; 9:3761.</a></li><li><a class="nounderline abstract_t">Larsen TB, Sørensen HT, Gislum M, Johnsen SP. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. Thromb Res 2007; 120:505.</a></li><li><a class="nounderline abstract_t">Virkus RA, Løkkegaard E, Lidegaard Ø, et al. Risk factors for venous thromboembolism in 1.3 million pregnancies: a nationwide prospective cohort. PLoS One 2014; 9:e96495.</a></li><li><a class="nounderline abstract_t">Han L, Jensen JT. Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk? Obstet Gynecol Clin North Am 2015; 42:683.</a></li><li><a class="nounderline abstract_t">Horton LG, Simmons KB, Curtis KM. Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review. Contraception 2016; 94:590.</a></li><li><a class="nounderline abstract_t">Rocha ALL, Campos RR, Miranda MMS, et al. Safety of hormonal contraception for obese women. Expert Opin Drug Saf 2017; 16:1387.</a></li><li><a class="nounderline abstract_t">Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51:283.</a></li><li><a class="nounderline abstract_t">Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71:319.</a></li><li><a class="nounderline abstract_t">Goldzieher JW, Moses LE, Averkin E, et al. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril 1971; 22:609.</a></li><li><a class="nounderline abstract_t">Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2014; :CD003987.</a></li><li><a class="nounderline abstract_t">Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 2001; 63:297.</a></li><li><a class="nounderline abstract_t">Edelman A, Jensen JT, Bulechowsky M, Cameron J. Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model. Hum Reprod 2011; 26:330.</a></li><li><a class="nounderline abstract_t">Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Int J Fertil Womens Med 1998; 43:73.</a></li><li><a class="nounderline abstract_t">Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001; 73:19.</a></li><li><a class="nounderline abstract_t">Bonny AE, Ziegler J, Harvey R, et al. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method. Arch Pediatr Adolesc Med 2006; 160:40.</a></li><li><a class="nounderline abstract_t">Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception. Int J Obes (Lond) 2005; 29:1252.</a></li><li><a class="nounderline abstract_t">Bonny AE, Britto MT, Huang B, et al. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol 2004; 17:109.</a></li><li><a class="nounderline abstract_t">Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2002; 15:79.</a></li><li><a class="nounderline abstract_t">Pantoja M, Medeiros T, Baccarin MC, et al. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception 2010; 81:107.</a></li><li><a class="nounderline abstract_t">Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007; 75:S60.</a></li><li><a class="nounderline abstract_t">Chi IC, Wilkens L. Interval tubal sterilization in obese women--an assessment of risks. Am J Obstet Gynecol 1985; 152:292.</a></li><li><a class="nounderline abstract_t">Chi IC, Wilkens LR, Reid SE. Prolonged hospital stay after laparoscopic sterilization. IPPF Med Bull 1984; 18:3.</a></li><li><a class="nounderline abstract_t">Chi I, Mumford SD, Laufe LE. Technical failures in tubal ring sterilization: Incidence, perceived reasons, outcome, and risk factors. Am J Obstet Gynecol 1980; 138:307.</a></li><li><a class="nounderline abstract_t">Jamieson DJ, Hillis SD, Duerr A, et al. Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization. Obstet Gynecol 2000; 96:997.</a></li><li><a class="nounderline abstract_t">Orbo A, Vereide A, Arnes M, et al. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG 2014; 121:477.</a></li><li><a class="nounderline abstract_t">Xu H, Wade JA, Peipert JF, et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012; 120:21.</a></li><li><a class="nounderline abstract_t">Bahamondes L, Brache V, Meirik O, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod 2015; 30:2527.</a></li><li><a class="nounderline abstract_t">Mornar S, Chan LN, Mistretta S, et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 2012; 207:110.e1.</a></li><li><a class="nounderline abstract_t">Sivin I, Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception 2001; 64:43.</a></li><li><a class="nounderline abstract_t">Morrell KM, Cremers S, Westhoff CL, Davis AR. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year. Contraception 2016; 93:263.</a></li><li><a class="nounderline abstract_t">Ali M, Akin A, Bahamondes L, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod 2016; 31:2491.</a></li><li><a class="nounderline abstract_t">Simmons KB, Edelman AB. Hormonal contraception and obesity. Fertil Steril 2016; 106:1282.</a></li><li><a class="nounderline abstract_t">Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 1. Use-effectiveness. Contraception 1977; 15:513.</a></li><li><a class="nounderline abstract_t">Jain J, Jakimiuk AJ, Bode FR, et al. Contraceptive efficacy and safety of DMPA-SC. Contraception 2004; 70:269.</a></li><li><a class="nounderline abstract_t">Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010; 81:487.</a></li><li><a class="nounderline abstract_t">Gerlach LS, Saldaña SN, Wang Y, et al. Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents. Clin Ther 2011; 33:182.</a></li><li><a class="nounderline abstract_t">Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception 2009; 80:346.</a></li><li><a class="nounderline abstract_t">Dinger JC, Cronin M, Möhner S, et al. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. Am J Obstet Gynecol 2009; 201:263.e1.</a></li><li><a class="nounderline abstract_t">Yamazaki M, Dwyer K, Sobhan M, et al. Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis. Contraception 2015; 92:445.</a></li><li><a class="nounderline abstract_t">Edelman AB, Cherala G, Munar MY, et al. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. Contraception 2014; 90:550.</a></li><li><a class="nounderline abstract_t">Dragoman MV, Simmons KB, Paulen ME, Curtis KM. Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review. Contraception 2017; 95:117.</a></li><li class="breakAll">Nextstellis (drospirenone and estetrol tablets). US FDA approved product information; Greenville NC: Mayne Pharma LLC; April 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214154s000lbl.pdf (Accessed on April 16, 2021).</li><li><a class="nounderline abstract_t">Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117:33.</a></li><li><a class="nounderline abstract_t">Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. Obstet Gynecol 2002; 99:820.</a></li><li><a class="nounderline abstract_t">Holt VL, Scholes D, Wicklund KG, et al. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105:46.</a></li><li><a class="nounderline abstract_t">Brunner Huber LR, Hogue CJ. The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception. Matern Child Health J 2005; 9:413.</a></li><li><a class="nounderline abstract_t">Vessey M. Oral contraceptive failures and body weight: findings in a large cohort study. J Fam Plann Reprod Health Care 2001; 27:90.</a></li><li><a class="nounderline abstract_t">Brunner Huber LR, Toth JL. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 2007; 166:1306.</a></li><li><a class="nounderline abstract_t">Burkman RT, Fisher AC, Wan GJ, et al. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009; 79:424.</a></li><li><a class="nounderline abstract_t">McNicholas C, Zhao Q, Secura G, et al. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 121:585.</a></li><li><a class="nounderline abstract_t">Kaneshiro B, Edelman A, Carlson N, et al. The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth. Contraception 2008; 77:234.</a></li><li class="breakAll">Nuvaring- etonogestrel and ethinyl eestradiol insert, extended release. US Food and Drug Administration (FDA) approved product information. Revised May, 2019. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on July 12, 2019).</li><li><a class="nounderline abstract_t">Archer DF, Merkatz RB, Bahamondes L, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health 2019; 7:e1054.</a></li><li><a class="nounderline abstract_t">Edelman A, Cherala G, Lim JY, Jensen JT. Contraceptive failures in overweight and obese combined hormonal contraceptive users. Obstet Gynecol 2013; 122:158.</a></li><li><a class="nounderline abstract_t">Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012; 207:39.e1.</a></li><li><a class="nounderline abstract_t">Dragoman M, Petrie K, Torgal A, et al. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception 2013; 87:432.</a></li><li class="breakAll">Xulane- norelgestromin and ethinyl estradiol patch. US Food and Drug Administration (FDA) approved product information. Revised April 2020. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 03, 2020).</li><li><a class="nounderline abstract_t">Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77:S13.</a></li><li class="breakAll">TWIRLA (levonorgestrel and ethinyl estradiol) transdermal system. US FDA approved product information; Grand Rapids, MI: Corium International Inc; February 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204017s000lbl.pdf (Accessed on March 12, 2020).</li><li><a class="nounderline abstract_t">Kaunitz AM, Archer DF, Mishell DR Jr, Foegh M. Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women. Am J Obstet Gynecol 2015; 212:318.e1.</a></li><li><a class="nounderline abstract_t">Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.</a></li><li><a class="nounderline abstract_t">Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril 2009; 92:1501.</a></li><li><a class="nounderline abstract_t">Gosman GG, King WC, Schrope B, et al. Reproductive health of women electing bariatric surgery. Fertil Steril 2010; 94:1426.</a></li><li><a class="nounderline abstract_t">Teitelman M, Grotegut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. Obes Surg 2006; 16:1457.</a></li><li><a class="nounderline abstract_t">Gerrits EG, Ceulemans R, van Hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg 2003; 13:378.</a></li><li><a class="nounderline abstract_t">Victor A, Odlind V, Kral JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am 1987; 16:483.</a></li><li><a class="nounderline abstract_t">Paulen ME, Zapata LB, Cansino C, et al. Contraceptive use among women with a history of bariatric surgery: a systematic review. Contraception 2010; 82:86.</a></li><li><a class="nounderline abstract_t">Ciangura C, Corigliano N, Basdevant A, et al. Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports. Contraception 2011; 84:649.</a></li><li><a class="nounderline abstract_t">Hillman JB, Miller RJ, Inge TH. Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients. J Womens Health (Larchmt) 2011; 20:533.</a></li></ol></div><div id="topicVersionRevision">Topic 5470 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19913155" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757656" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Body mass index and sexual behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051107" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Contraceptive use by diabetic and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964284" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Family planning for obese women: challenges and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27537097" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hormonal contraceptives for contraception in overweight or obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19631786" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23153898" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472113" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7859407" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Drug metabolism in malnutrition and obesity: clinical concerns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6801963" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Twenty-four-hour energy expenditure and resting metabolic rate in obese, moderately obese, and control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7364059" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Variation of ethinylestradiol blood levels among healthy women using oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1184730" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influence of body weight on estradiol metabolism in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664386" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30681544" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31053605" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : FSRH Guideline (April 2019) Overweight, Obesity and Contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35926206" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of Progestogens and Venous Thromboembolism Among Women of Reproductive Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36103980" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Obesity and contraceptive use: impact on cardiovascular risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17257657" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium: a population-based nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24788753" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk factors for venous thromboembolism in 1.3 million pregnancies: a nationwide prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598309" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263039" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Combined hormonal contraceptive use among obese women and risk for cardiovascular events: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988524" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Safety of hormonal contraception for obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628201" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15854630" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4105854" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477630" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Combination contraceptives: effects on weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11672550" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21126966" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Combined oral contraceptives and body weight: do oral contraceptives cause weight gain? A primate model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609206" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124744" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389209" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15997247" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Weight, fat mass, and central distribution of fat increase when women use depot-medroxyprogesterone acetate for contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050987" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12057528" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20103446" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17531619" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Neoplasia with use of intrauterine devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4003474" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Interval tubal sterilization in obese women--an assessment of risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12266321" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Prolonged hospital stay after laparoscopic sterilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6448003" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Technical failures in tubal ring sterilization: Incidence, perceived reasons, outcome, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11084192" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Complications of interval laparoscopic tubal sterilization: findings from the United States Collaborative Review of Sterilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286192" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22678035" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409014" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22717269" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pharmacokinetics of the etonogestrel contraceptive implant in obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11535213" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26577754" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671673" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27565257" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hormonal contraception and obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/880823" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxyprogesterone acetate. 1. Use-effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451329" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Contraceptive efficacy and safety of DMPA-SC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472115" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21397330" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751857" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Progestogen-only contraceptive use in obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481720" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Oral contraceptive effectiveness according to body mass index, weight, age, and other factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26247330" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070547" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27823942" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27823942" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21213475" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978293" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Body weight and risk of oral contraceptive failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625141" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Body mass index, weight, and oral contraceptive failure risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235025" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12457519" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Oral contraceptive failures and body weight: findings in a large cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17785712" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19442776" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Association between efficacy and body weight or body mass index for two low-dose oral contraceptives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23635622" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Contraceptive failures in overweight and obese combined hormonal contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342645" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18342645" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : The relationship between body mass index and unintended pregnancy: results from the 2002 National Survey of Family Growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31231065" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23787930" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Contraceptive failures in overweight and obese combined hormonal contraceptive users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22727346" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312933" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312933" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849631" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849631" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25220709" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21477680" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Contraceptive failure in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665703" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Impact of bariatric surgery on female reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815190" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reproductive health of women electing bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17132411" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The impact of bariatric surgery on menstrual patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12841897" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Contraceptive treatment after biliopancreatic diversion needs consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2449395" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682146" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Contraceptive use among women with a history of bariatric surgery: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22078197" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Etonorgestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21413894" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Menstrual concerns and intrauterine contraception among adolescent bariatric surgery patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
